{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:31:54Z","timestamp":1793910714160,"version":"4.8.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.urolonc.2021.11.012","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T18:37:25Z","timestamp":1640111845000},"page":"105.e1-105.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Juhyeon","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-8861","authenticated-orcid":false,"given":"Seung-Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-5299","authenticated-orcid":false,"given":"Hyeong Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2021.11.012_bib0001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"International journal of cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40615-014-0071-x","article-title":"African-American men with low-risk prostate cancer: Modern treatment and outcome trends","volume":"2","author":"Obirieze","year":"2015","journal-title":"Journal of racial and ethnic health disparities"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0003","first-page":"1","article-title":"Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer","volume":"7","author":"Kim","year":"2016","journal-title":"Nature communications"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.med.60.042307.110714","article-title":"Biomarkers for prostate cancer","volume":"60","author":"Makarov","year":"2009","journal-title":"Annual review of medicine"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0005","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.23373","article-title":"Active surveillance for early-stage prostate cancer: review of the current literature","volume":"112","author":"Dall'Era","year":"2008","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0006","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.bjc.6605422","article-title":"Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer","volume":"101","author":"Heijnsdijk","year":"2009","journal-title":"British journal of cancer"},{"issue":"10-11","key":"10.1016\/j.urolonc.2021.11.012_bib0007","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinbiochem.2013.10.023","article-title":"Clinical use of novel urine and blood based prostate cancer biomarkers: a review","volume":"47","author":"Dijkstra","year":"2014","journal-title":"Clinical biochemistry"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"European urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0009","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","article-title":"Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer","volume":"65","author":"Leyten","year":"2014","journal-title":"European urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2010.11.026","article-title":"A panel of TMPRSS2: ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity","volume":"59","author":"Nguyen","year":"2011","journal-title":"European urology"},{"issue":"6","key":"10.1016\/j.urolonc.2021.11.012_bib0011","first-page":"620","article-title":"Regulators of gene expression as biomarkers for prostate cancer","volume":"2","author":"Willard","year":"2012","journal-title":"American journal of cancer research"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10408363.2014.906130","article-title":"Nucleic acid-based tissue biomarkers of urologic malignancies","volume":"51","author":"Dietrich","year":"2014","journal-title":"Critical reviews in clinical laboratory sciences"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2017.08.009","article-title":"Urinary RNA-based biomarkers for prostate cancer detection","volume":"473","author":"Martignano","year":"2017","journal-title":"Clinica Chimica Acta"},{"issue":"12","key":"10.1016\/j.urolonc.2021.11.012_bib0014","first-page":"5141","article-title":"LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer","volume":"8","author":"Ma","year":"2016","journal-title":"American journal of translational research"},{"issue":"10","key":"10.1016\/j.urolonc.2021.11.012_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nature reviews Drug discovery"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrg3162","article-title":"MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship","volume":"13","author":"Pasquinelli","year":"2012","journal-title":"Nature Reviews Genetics"},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.012_bib0017","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrurol.2010.45","article-title":"Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors","volume":"7","author":"Schaefer","year":"2010","journal-title":"Nature Reviews Urology"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2014\/591703","article-title":"Noncoding RNAs as novel biomarkers in prostate cancer","volume":"2014","author":"R\u00f6nnau","year":"2014","journal-title":"BioMed research international"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0019","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molmed.2014.03.005","article-title":"Long noncoding RNAs and prostate carcinogenesis: the missing \u2018linc\u2019?","volume":"20","author":"Walsh","year":"2014","journal-title":"Trends in molecular medicine"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0020","first-page":"8","article-title":"Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma","volume":"2014","author":"Li","year":"2014","journal-title":"BioMed research international"},{"issue":"19","key":"10.1016\/j.urolonc.2021.11.012_bib0021","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/j.jmb.2012.11.024","article-title":"Posttranscriptional gene regulation by long noncoding RNA","volume":"425","author":"Yoon","year":"2013","journal-title":"Journal of molecular biology"},{"issue":"13","key":"10.1016\/j.urolonc.2021.11.012_bib0022","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1101\/gad.1800909","article-title":"Long noncoding RNAs: functional surprises from the RNA world","volume":"23","author":"Wilusz","year":"2009","journal-title":"Genes & development"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tplants.2011.10.008","article-title":"Long noncoding RNA: unveiling hidden layer of gene regulatory networks","volume":"17","author":"Kim","year":"2012","journal-title":"Trends in plant science"},{"issue":"61","key":"10.1016\/j.urolonc.2021.11.012_bib0024","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.18632\/oncotarget.27284","article-title":"The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer","volume":"10","author":"Lemos","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.12.001","article-title":"Urine PCA3 and TMPRSS2: ERG using cancer-specific markers to detect cancer","volume":"65","author":"Tomlins","year":"2014","journal-title":"European urology"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0026","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1007\/s13277-016-5012-3","article-title":"PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells","volume":"37","author":"Lemos","year":"2016","journal-title":"Tumor Biology"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0027","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","article-title":"Toward the detection of prostate cancer in urine: a critical analysis","volume":"189","author":"Truong","year":"2013","journal-title":"The Journal of urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0028","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2011.10.133","article-title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion","volume":"187","author":"Salagierski","year":"2012","journal-title":"The Journal of urology"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0029","first-page":"1","volume":"301","author":"Day","year":"2011","journal-title":"PCA3: from basic molecular science to the clinical lab. Cancer letters"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/aja.2013.6","article-title":"Urinary biomarkers for prostate cancer: a review","volume":"15","author":"Hessels","year":"2013","journal-title":"Asian journal of andrology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-06-2679","article-title":"The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance","volume":"13","author":"van Gils","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrurol.2011.10","article-title":"Diagnostic performance of the PCA3 urine test","volume":"8","author":"Lee","year":"2011","journal-title":"Nature Reviews Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0033","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2010.06.039","article-title":"Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test","volume":"58","author":"Roobol","year":"2010","journal-title":"European urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1481-9","article-title":"SOX12 promotes colorectal cancer cell proliferation and metastasis by regulating asparagine synthesis","volume":"10","author":"Du","year":"2019","journal-title":"Cell death & disease"},{"issue":"13","key":"10.1016\/j.urolonc.2021.11.012_bib0035","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.ejca.2013.04.026","article-title":"Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer","volume":"49","author":"Ren","year":"2013","journal-title":"European journal of cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0036","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12032-011-0004-z","article-title":"Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation","volume":"29","author":"Lai","year":"2012","journal-title":"Medical oncology"},{"issue":"22","key":"10.1016\/j.urolonc.2021.11.012_bib0037","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1016\/j.febslet.2010.10.008","article-title":"MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes","volume":"584","author":"Tano","year":"2010","journal-title":"FEBS letters"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0038","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1349-7006.2006.00147.x","article-title":"Phenotypic characterization of endometrial stromal sarcoma of the uterus","volume":"97","author":"Yamada","year":"2006","journal-title":"Cancer science"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0039","first-page":"169","article-title":"MALAT-1: a long non-coding RNA and its important 3\u2032end functional motif in colorectal cancer metastasis","volume":"39","author":"Xu","year":"2011","journal-title":"International journal of oncology"},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.012_bib0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/cr.2012.30","article-title":"RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings","volume":"22","author":"Ren","year":"2012","journal-title":"Cell research"},{"issue":"6","key":"10.1016\/j.urolonc.2021.11.012_bib0041","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.juro.2013.07.001","article-title":"Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer","volume":"190","author":"Ren","year":"2013","journal-title":"The Journal of urology"},{"issue":"7291","key":"10.1016\/j.urolonc.2021.11.012_bib0042","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.urolonc.2021.11.012_bib0043","doi-asserted-by":"crossref","first-page":"20872","DOI":"10.18632\/oncotarget.25038","article-title":"The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer","volume":"9","author":"Arriaga-Canon","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0044","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/ijms18020473","article-title":"Current insights into long non-coding RNAs (LncRNAs) in prostate cancer","volume":"18","author":"Smolle","year":"2017","journal-title":"International journal of molecular sciences"},{"issue":"14","key":"10.1016\/j.urolonc.2021.11.012_bib0045","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/onc.2009.4","article-title":"The SWI\/SNF complex and cancer","volume":"28","author":"Reisman","year":"2009","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0046","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ng.2771","article-title":"The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI\/SNF complex","volume":"45","author":"Prensner","year":"2013","journal-title":"Nature genetics"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0047","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2015.12.003","article-title":"Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer","volume":"70","author":"Mehra","year":"2016","journal-title":"European urology"},{"issue":"13","key":"10.1016\/j.urolonc.2021.11.012_bib0048","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S1470-2045(14)71113-1","article-title":"RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1","volume":"15","author":"Prensner","year":"2014","journal-title":"The lancet oncology"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0049","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.onc.1207069","article-title":"Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients","volume":"23","author":"Petrovics","year":"2004","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.urolonc.2021.11.012_bib0050","doi-asserted-by":"crossref","first-page":"15481","DOI":"10.18632\/oncotarget.7139","article-title":"Regulation of androgen receptor splice variant AR3 by PCGEM1","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.urolonc.2021.11.012_bib0051","doi-asserted-by":"crossref","first-page":"12216","DOI":"10.1073\/pnas.97.22.12216","article-title":"PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer","volume":"97","author":"Srikantan","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0314-4","article-title":"The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo","volume":"14","author":"Parolia","year":"2015","journal-title":"Molecular cancer"},{"issue":"7464","key":"10.1016\/j.urolonc.2021.11.012_bib0053","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature12451","article-title":"lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs","volume":"500","author":"Yang","year":"2013","journal-title":"Nature"},{"issue":"41","key":"10.1016\/j.urolonc.2021.11.012_bib0054","doi-asserted-by":"crossref","first-page":"36152","DOI":"10.1074\/jbc.M111.265124","article-title":"Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells","volume":"286","author":"Yang","year":"2011","journal-title":"Journal of Biological Chemistry"},{"issue":"14","key":"10.1016\/j.urolonc.2021.11.012_bib0055","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer research"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb0322s30","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids","volume":"30","author":"Th\u00e9ry","year":"2006","journal-title":"Current protocols in cell biology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0057","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/epr.09.17","article-title":"Exosomes: proteomic insights and diagnostic potential","volume":"6","author":"Simpson","year":"2009","journal-title":"Expert review of proteomics"},{"issue":"10","key":"10.1016\/j.urolonc.2021.11.012_bib0058","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.bjc.6605058","article-title":"Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer","volume":"100","author":"Nilsson","year":"2009","journal-title":"British journal of cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0059","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1515\/cclm-2015-0599","article-title":"Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes","volume":"54","author":"Hendriks","year":"2016","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"9","key":"10.1016\/j.urolonc.2021.11.012_bib0060","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/pros.23355","article-title":"Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine","volume":"77","author":"Pellegrini","year":"2017","journal-title":"The Prostate"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0061","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2017.08.002","article-title":"Urinary biomarkers in prostate cancer detection and monitoring progression","volume":"118","author":"Wu","year":"2017","journal-title":"Critical reviews in oncology\/hematology"},{"issue":"7333","key":"10.1016\/j.urolonc.2021.11.012_bib0062","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.urolonc.2021.11.012_bib0063","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1038\/sj.onc.1208518","article-title":"Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome","volume":"24","author":"Petrovics","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0064","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/modpathol.2009.193","article-title":"Prevalence of TMPRSS2\u2013ERG and SLC45A3\u2013ERG gene fusions in a large prostatectomy cohort","volume":"23","author":"Esgueva","year":"2010","journal-title":"Modern Pathology"},{"issue":"6","key":"10.1016\/j.urolonc.2021.11.012_bib0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1756287213495915","article-title":"Biomarkers in prostate cancer surveillance and screening: past, present, and future","volume":"5","author":"Cary","year":"2013","journal-title":"Therapeutic advances in urology"},{"issue":"7","key":"10.1016\/j.urolonc.2021.11.012_bib0066","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1440-1827.2011.02675.x","article-title":"Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients","volume":"61","author":"Furusato","year":"2011","journal-title":"Pathology international"},{"issue":"9","key":"10.1016\/j.urolonc.2021.11.012_bib0067","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1007\/s13277-016-5116-9","article-title":"TMPRSS2: ERG fusion gene occurs less frequently in Chinese patients with prostate cancer","volume":"37","author":"Jiang","year":"2016","journal-title":"Tumor Biology"},{"issue":"5","key":"10.1016\/j.urolonc.2021.11.012_bib0068","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pros.21265","article-title":"TMPRSS2\u2013ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients","volume":"71","author":"Magi-Galluzzi","year":"2011","journal-title":"The Prostate"},{"issue":"10","key":"10.1016\/j.urolonc.2021.11.012_bib0069","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1593\/neo.06625","article-title":"Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer","volume":"8","author":"Laxman","year":"2006","journal-title":"Neoplasia (New York, NY)"},{"issue":"17","key":"10.1016\/j.urolonc.2021.11.012_bib0070","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1158\/1078-0432.CCR-07-0700","article-title":"Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer","volume":"13","author":"Hessels","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0071","series-title":"Urologic Oncology: Seminars and Original Investigations","first-page":"566","article-title":"Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer","author":"Salami","year":"2013"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0072","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/S0022-2275(20)31983-0","article-title":"Subcellular localization and physiological role of \u03b1-methylacyl-CoA racemase","volume":"41","author":"Ferdinandusse","year":"2000","journal-title":"Journal of lipid research"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0073","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00000478-200111000-00007","article-title":"P504S: a new molecular marker for the detection of prostate carcinoma","volume":"25","author":"Jiang","year":"2001","journal-title":"The American journal of surgical pathology"},{"issue":"13","key":"10.1016\/j.urolonc.2021.11.012_bib0074","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.287.13.1662","article-title":"\u03b1-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer","volume":"287","author":"Rubin","year":"2002","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0075","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.urology.2012.06.017","article-title":"Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer","volume":"80","author":"Li","year":"2012","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0076","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1593\/neo.08922","article-title":"Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer","volume":"10","author":"Varambally","year":"2008","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0077","doi-asserted-by":"crossref","first-page":"e43470","DOI":"10.1371\/journal.pone.0043470","article-title":"Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics","volume":"7","author":"March-Villalba","year":"2012","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.urolonc.2021.11.012_bib0078","doi-asserted-by":"crossref","first-page":"e66855","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0079","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.eururo.2017.03.036","article-title":"Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features","volume":"73","author":"Karnes","year":"2018","journal-title":"European urology"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/pcan.2013.49","article-title":"A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy","volume":"17","author":"Ross","year":"2014","journal-title":"Prostate cancer and prostatic diseases"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0081","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"European urology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0082","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"The lancet oncology"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0083","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"cell"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0084","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2015\/125094","article-title":"MicroRNAs as potential biomarkers in cancer: opportunities and challenges","volume":"2015","author":"Lan","year":"2015","journal-title":"BioMed research international"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","article-title":"MicroRNAs in body fluids\u2014the mix of hormones and biomarkers","volume":"8","author":"Cortez","year":"2011","journal-title":"Nature reviews Clinical oncology"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0086","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.eururo.2015.12.054","article-title":"The potential of microRNAs as prostate cancer biomarkers","volume":"70","author":"Fabris","year":"2016","journal-title":"European urology"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0087","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/bjc.2011.595","article-title":"Changes in circulating microRNA levels associated with prostate cancer","volume":"106","author":"Bryant","year":"2012","journal-title":"British journal of cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0088","first-page":"115","article-title":"Circulating MicroRNA as biomarkers: An update in prostate cancer","volume":"3","author":"Srivastava","year":"2011","journal-title":"Molecular and cellular pharmacology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.11.012_bib0089","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ijc.25376","article-title":"Circulating miRNAs are correlated with tumor progression in prostate cancer","volume":"128","author":"Brase","year":"2011","journal-title":"International journal of cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0090","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1158\/0008-5472.CAN-10-1229","article-title":"Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients","volume":"71","author":"Moltzahn","year":"2011","journal-title":"Cancer research"},{"issue":"1","key":"10.1016\/j.urolonc.2021.11.012_bib0091","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1186\/1471-2407-14-930","article-title":"MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers","volume":"14","author":"Jackson","year":"2014","journal-title":"BMC cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2021.11.012_bib0092","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/onc.2015.176","article-title":"A microRNA code for prostate cancer metastasis","volume":"35","author":"Bonci","year":"2016","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.urolonc.2021.11.012_bib0093","first-page":"2201","article-title":"MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer","volume":"20","author":"Sha","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0094","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M608939200","article-title":"An E2F\/miR-20a autoregulatory feedback loop","volume":"282","author":"Sylvestre","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"31","key":"10.1016\/j.urolonc.2021.11.012_bib0095","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1038\/onc.2008.72","article-title":"MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene","volume":"27","author":"Lu","year":"2008","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.urolonc.2021.11.012_bib0096","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1158\/0008-5472.CAN-10-2579","article-title":"IFN Induces miR-21 through a Signal transducer and activator of transcription 3\u2013dependent pathway as a suppressive negative feedback on IFN-induced apoptosis","volume":"70","author":"Yang","year":"2010","journal-title":"Cancer research"},{"issue":"18","key":"10.1016\/j.urolonc.2021.11.012_bib0097","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/0008-5472.CAN-09-1448","article-title":"miR-21: an androgen receptor\u2013regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth","volume":"69","author":"Ribas","year":"2009","journal-title":"Cancer research"},{"issue":"8","key":"10.1016\/j.urolonc.2021.11.012_bib0098","doi-asserted-by":"crossref","first-page":"e72400","DOI":"10.1371\/journal.pone.0072400","article-title":"Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1","volume":"8","author":"Haflidad\u00f3ttir","year":"2013","journal-title":"PloS one"},{"issue":"19","key":"10.1016\/j.urolonc.2021.11.012_bib0099","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.18632\/oncotarget.2396","article-title":"Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia","volume":"5","author":"Ma","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2021.11.012_bib0100","series-title":"Circulating Nucleic Acids in Serum and Plasma\u2013CNAPS IX","first-page":"9","article-title":"Cell-free miRNA-141 and miRNA-205 as prostate cancer biomarkers","author":"Osipov","year":"2016"},{"issue":"2","key":"10.1016\/j.urolonc.2021.11.012_bib0101","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/toxsci\/kfu002","article-title":"Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic","volume":"138","author":"Ngalame","year":"2014","journal-title":"Toxicological sciences"},{"issue":"4","key":"10.1016\/j.urolonc.2021.11.012_bib0102","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3892\/etm.2014.1846","article-title":"microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression","volume":"8","author":"Tong","year":"2014","journal-title":"Experimental and therapeutic medicine"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:40Z","timestamp":1761042280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921005093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1078143921005093"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}